Keyphrases
Plasminogen Activator inhibitor-1 (PAI-1)
100%
Antagonism
100%
Differential Effects
100%
Angiotensin II Type 1 Receptor (AT1R)
100%
Angiotensin Type I Receptor
100%
Losartan
75%
Ramipril
50%
ACE Inhibition
50%
Hydrochlorothiazide
37%
Plasminogen Activator
25%
Metabolic
12%
Insulin Resistance
12%
Risk Factors
12%
Tissue Plasminogen Activator (t-PA)
12%
Blood Pressure
12%
Myocardial Infarction
12%
Body Mass Index
12%
Fasting Plasma Glucose
12%
Treatment Duration
12%
Pressure Effect
12%
Time Interaction
12%
Serum Triglycerides
12%
Receptor Antagonism
12%
Renin-angiotensin-aldosterone System
12%
Hypertensive Subjects
12%
Agricultural and Biological Sciences
Plasminogen Activator Inhibitor-1
100%
Angiotensin II Receptor Type 1
100%
Losartan
75%
Ramipril
50%
Blood Plasma
37%
Hydrochlorothiazide
37%
Angiotensin
25%
Plasminogen Activator
25%
Triglyceride
12%
Risk Factor
12%
Body Mass Index
12%
Receptor
12%
Blood Pressure
12%
Myocardial Infarction
12%
Aldosterone
12%
Renin
12%
Tissue Plasminogen Activator
12%
Pharmacology, Toxicology and Pharmaceutical Science
Plasminogen Activator Inhibitor 1
100%
Angiotensin 1 Receptor
100%
Losartan
75%
Ramipril
50%
Hydrochlorothiazide
37%
Plasminogen Activator
25%
Triacylglycerol
12%
Heart Infarction
12%
Fibrinolytic Agent
12%
Tissue Plasminogen Activator
12%
Renin
12%
Angiotensin
12%
Aldosterone
12%
Angiotensin Receptor
12%